SpyGlass takes lens supplier in-house for $13m as glaucoma implant nears late-stage milestones
The US ophthalmic developer has bought a Santen-owned lens business and posted long-term follow-up from its lead bimatoprost implant, while a second implant enters human testing.
SpyGlass Pharma has taken ownership of a key manufacturing input for its lead glaucoma product. The company said it completed the purchase of Advanced Vision Science (AVS) from Japan's Santen in October, paying roughly $13 million. The disclosure came with its third-quarter 2026 update on 11 November.
The rationale is supply. AVS makes intraocular lenses (IOLs), which form part of the Bimatoprost Drug Pad-IOL System, a drug-device combination now in Phase 3 for open-angle glaucoma and ocular hypertension. Owning the lens maker removes a dependency on an outside source for a component of a product in pivotal development. The facts provided do not say what the transaction means for any ongoing supply arrangements with Santen, or how the lens business will be run.
On the clinical side, SpyGlass reported four-year first-in-human results for the Drug Pad-IOL programme: a mean reduction in intraocular pressure of 37%, and no product-related adverse events so far. These come from an early-stage study, so they say little about how the product will fare against the controlled comparisons expected in Phase 3.
The company also said it has begun implanting patients with a second candidate, the Bimatoprost-Drug Ring System (BIM-DRS), in a first-in-human study. That gives SpyGlass a second delivery format built around the same drug. Cash stood at $215.8 million at the quarter's end, which management expects to cover operations through 2028.
Why it matters
- Buying its lens supplier gives SpyGlass direct control over a component of a drug-device product heading through Phase 3, a point manufacturing and quality teams will track.
- Four years of follow-up without product-related adverse events is a useful long-term safety marker for sustained-release eye implants, though it comes from a first-in-human study.
- BIM-DRS entering human use gives SpyGlass a second bimatoprost delivery approach alongside the lens-based system.
- A stated runway through 2028 indicates the company believes the Phase 3 programme is funded for the medium term.
Company's press release (SEC filing): SpyGlass Pharma, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
